Alright vault fam —
In February 2026, the FDA finalized its 503A bulk drug substance determination for BPC-157, TB-500 (Thymosin Beta-4), CJC-1295, and Ipamorelin — moving all four from Category 2 (under evaluation) to Category 1. This is not a ban on the molecules themselves, but it ends the legal pathway that U.S. licensed compounding pharmacies have used to supply them under prescription.
Compounds covered in this article
WHAT CHANGED AND WHAT IT MEANS
Category 1 under 503A designates substances that present 'demonstrably difficult issues of safety or effectiveness' when used in compounding without FDA oversight. For BPC-157, TB-500, CJC-1295, and Ipamorelin, this finalization ends their availability through 503A and 503B compounding pharmacies — the route that telehealth providers and wellness clinics have used to legally supply them under prescription.
The practical impact: pharmacies filling prescriptions for these peptides must cease production. Patients currently mid-protocol face supply disruption. Research use under IRB supervision remains unaffected — FDA action applies to commercial compounding, not academic or clinical research settings. International sources remain legal for personal import under FDA personal use discretion guidelines, though enforcement is inconsistent.
HOW THE 503A CATEGORY SYSTEM WORKS
Under the Drug Quality and Security Act (DQSA, 2013), 503A pharmacies can use bulk drug substances only if those substances appear on an FDA-approved list. The Pharmacy Compounding Advisory Committee (PCAC) evaluates nominated substances and recommends their category. Category 1 removes a substance; Category 2 means under evaluation while compounding continues; Category 3 means approved for compounding use.
BPC-157 and TB-500 had long occupied Category 2 — a legal gray zone where compounding continued while the FDA deliberated. The February 2026 finalization closes that window permanently. Pharmacies can no longer legally compound or dispense these substances under 503A or 503B.
WHY THE FDA CITED THESE FOUR
The FDA's determination cited three primary concerns: (1) lack of adequate human clinical trial data demonstrating safety and effectiveness; (2) absence of standardized manufacturing processes and specifications for pharmaceutical-grade production; (3) unclear dosing guidance that creates patient risk. The FDA did not dispute the animal study data — it noted that the clinical evidence base does not yet meet the threshold required for compounding access.
This was widely anticipated following the 2024 PCAC meetings where these substances were flagged. The reclassification is not a safety crisis — it is a compounding access issue. PepVault will update all affected index entries and track any regulatory response, citizen petition, or appeal from the compounding pharmacy industry.
Sources & References
